COPD & Emphysema Support Group
COPD is a progressive disease characterized by airflow obstruction or limitation. Emphysema is characterized by loss of elasticity of the lung tissue, destruction of structures supporting the alveoli and of capillaries feeding the alveoli. Both have symptoms that include shortness of breath, among other respiratory troubles. If you are a COPD or Emphysema sufferer, join...
Reuters
2:35 p.m. CDT, July 23, 2012
The Food and Drug Administration approved the twice-daily drug, to be sold as Tudorza Pressair, to treat symptoms of chronic obstructive pulmonary disease (COPD), a serious lung disease that makes breathing difficult and is often caused by smoking.
http://www.chicagotribune.com/business/breaking/chi-fda-oks-forest-labs-drug-for-smokers-cough-20120723,0,4330734.story
Aclidinium Bromide
Novel, potent, long-acting
anticholinergic bronchodilator
Long residence time at M3 receptor long duration
of action
Rapid plasma hydrolysis low systemic exposure
and rapid clearance
Low potential for drug-drug interactions
Important new treatment option in the
armamentarium of COPD therapies
Demonstrated clinical safety and effectiveness of the
400 g BID dose
Pressair Dry Powder Inhaler Device
Convenient and easy to use
Small and portable
No need to load capsules
Press and breathe
Successful dosing is confirmed
Tactile, visual, and auditory cues
Works reliably in patie
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM294001.pdf
This is good news, another new medication approved by FDA for us:)
Anyone giving Tudorza Pressair a try let us know how you do with it.
Easy breathing to all of you,
Love
Holly
2:35 p.m. CDT, July 23, 2012
The Food and Drug Administration approved the twice-daily drug, to be sold as Tudorza Pressair, to treat symptoms of chronic obstructive pulmonary disease (COPD), a serious lung disease that makes breathing difficult and is often caused by smoking.
http://www.chicagotribune.com/business/breaking/chi-fda-oks-forest-labs-drug-for-smokers-cough-20120723,0,4330734.story
Aclidinium Bromide
Novel, potent, long-acting
anticholinergic bronchodilator
Long residence time at M3 receptor long duration
of action
Rapid plasma hydrolysis low systemic exposure
and rapid clearance
Low potential for drug-drug interactions
Important new treatment option in the
armamentarium of COPD therapies
Demonstrated clinical safety and effectiveness of the
400 g BID dose
Pressair Dry Powder Inhaler Device
Convenient and easy to use
Small and portable
No need to load capsules
Press and breathe
Successful dosing is confirmed
Tactile, visual, and auditory cues
Works reliably in patie
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM294001.pdf
This is good news, another new medication approved by FDA for us:)
Anyone giving Tudorza Pressair a try let us know how you do with it.
Easy breathing to all of you,
Love
Holly
it is always good to see another option come on the market for COPD.
Got a chuckle by it being referred to as "A smokers cough commonly called COPD". Think there were some steps missing in that leap from a cough to COPD.
Thanks for posting this.